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The article presents the advantages and limitations of adaptive 
clinical trials for assessing the effectiveness of medical interventions 
and specifies the conditions that contributed to their development 
and implementation in clinical practice. I advance two arguments 
by discussing different cases of adaptive trials. The normative 
argument is that responsible adaptation should be taken seriously 
as a new way of doing clinical research insofar as a valid 
justification, sufficient understanding, and adequate operational 
conditions are provided. The second argument is historical. The 
development of adaptive trials can be related to lessons learned 
from research in cases of urgency and to the decades-long efforts to 
end the productivity crisis of pharmaceutical research, which led to 
the emergence of translational, personalized, and, recently, 
precision medicine movements. 
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Adaptive clinical trials have been at the forefront of the efforts to mitigate 
the ongoing coronavirus pandemic due to their shorter duration and 
flexible design, which allows for accelerated assessment and the timely 
implementation of new vaccines and therapies (WHO 2020; Stallard et al. 
2020; Branch-Elliman, Elwy, and Monach 2020; London and Kimmelman 
2020). Adaptive trials are a subset of randomized controlled trials (RCTs), 
in which one or more features of the design can be changed during the 
trial’s course based on interim results from the data accumulated early on.1 
Although they use control groups and randomization of patients to either 
the experimental or the control treatment, they differ from the standard 
RCTs by the absence of a fixed design. A fixed trial is first designed, 
conducted, and then analyzed upon completion, with no intermediate steps. 
In cases in which quick action is needed and standard RCT evidence is not 
available and takes too long to acquire, observational and other types of 
evidence need to provide temporary guidance. Adaptive design trials 
enable this by generating results based on observing patient responses and 
conducting interim analyses, in this way integrating evidence from 
experimentation with observational evidence and preclinical data.  
 
Recently, London and Kimmelman have argued for the usage of multi-arm 
and seamless adaptive design trials, stating that “one lesson of the current 
outbreak is that expeditious research in a crisis situation is feasible” (2020, 
477). If responsible expeditious research via adaptive design is feasible, 
should its methodology be used more widely, also in non-crisis contexts? 
To what extent are adaptive trials a valid, or even superior alternative to 
fixed RCTs in clinical research? If yes, on which grounds and under what 
circumstances? A conjoined ethical and epistemological discussion is in 
place. The aim of this paper is twofold: to outline some of the advantages 
and limitations of adaptive trials, and to specify the conditions that 
contributed to their development and implementation in clinical practice. 
This will make a case for their usage, but not in all contexts. 
 
The first argument advanced in this paper is normative: responsible 
adaptation should be taken seriously as a new way of doing clinical 
research, but only insofar as a valid justification, sufficient understanding, 
and adequate operational conditions for the introduction of adaptive 
measures are provided. The most common obstacles to their 
implementation are local and practical, rather than general and principled. 
The greatest danger to the integrity of clinical research is shared across 
 
1 There can be non-randomized and uncontrolled trials, including adaptive trials, but they do not satisfy 
regulatory standards and their limitations are well documented. 
Daria Jadreškić: Adapt to translate – adaptive clinical trials and biomedical innovation 
 
 7 
different designs: it is, on the one hand, the ineliminable uncertainty of 
experimenting, and on the other, it is the intrusion of unwanted bias, such 
as sponsorship bias, or more broadly, preference bias (Wilholt 2009). 
However, both dangers hold for fixed and adaptive trials alike, and should 
not downplay positive aspects of adaptation. 
 
The second argument is historical: the presence of adaptive trials as one of 
the potential drivers of biomedical innovation can be related not only to 
lessons learned from research in cases of urgency, but also to the decades-
long efforts to end the productivity crisis of pharmaceutical research, 
which led to the emergence of translational, personalized, and more 
recently, precision medicine movements. These efforts have motivated 
new methods, organization, and relations between research stakeholders. 
Biomedical innovation has been spurred by investments in education and 
training in translational research, promotion of interdisciplinarity, 
collection of a variety of data- and bio-banks, developments in 
bioinformatics, calls for inclusion of patients in healthcare decision-
making, and a general focus on the (re)organization of basic-clinical 
research interface via private-public partnerships. This has contributed to 
a broadening of clinical research teams to include experts in 
bioinformatics, statistics, and other big data skills which have enabled, 
among else, innovations in clinical trial design.   
 
The ratio of randomization to different treatment arms in adaptive trials 
may not be equal or consistent throughout the trial’s course, so the term 
‘adaptive’ sometimes primarily characterizes randomization, such as in 
“outcome-adaptive randomization” (Berry 2011). Other adaptations 
include changes in sample size, treatment dose, or patient allocation ratio 
(Pallmann et al. 2018, 2). Adaptation can also mean abandoning treatment 
arms, stopping the trial early because of evident success or a lack of 
efficacy, or identifying and recruiting patients who are most likely to 
benefit from the treatment. Adaptive trials can assess several treatments in 
a single trial, or seamlessly merge different trial phases into only one trial. 
Adaptations need to be preplanned and modeled before the onset of the 
trial to preserve its integrity and generate valid results (Pallmann et al. 
2018, 10-11). Without planning, rigorous execution and analysis, there is 
an increased risk of introducing bias into the trial. Results can be difficult 
to interpret due to a higher tolerance for false positives, in other words, for 
cases of observed beneficial effects whose cause is wrongly attributed to 
the experimental treatment.  
 
A departure from the fixed RCT standard predates the coronavirus 
pandemic. Adaptive trials have been used both in urgent circumstances 
such as the 2013-2016 Ebola virus (Henao-Restrepo et al. 2017; Calain 
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2018) and earlier the AIDS epidemic (Epstein 1996), but also for 
evaluating therapies in the domain of precision medicine. If the mechanism 
of the experimental intervention is well understood, for example, because 
of the possibility to match therapies with subgroups of patients based on 
genomic data, the trial can be designed to recruit only patients who will 
benefit from the treatment. Adaptive trials are thus being increasingly used 
for evaluating the efficacy of cancer therapies and other targeted 
interventions (Riley 2016; Garralda et al. 2019), and both EMA and FDA 
have included them in their regulatory schemes (EMA 2017; FDA 2019). 
 
I section 2, I discuss two cases of adaptive trials: the azidothymidine (AZT) 
trial in the 1980s and Ebola ca Suffit! trial in 2015. These two trials present 
milestones for the usage of adaptation in the context of crisis. Motivations 
for conducting adaptive trials are identified, as well as the trade-offs 
permeating the decision to rely on them. Section 3 puts forward the bulk 
of the normative argument. I draw on London and Kimmelmann’s (2020) 
lessons from the ongoing coronavirus pandemic to show that reliable 
adaptation is alive and well and that the tension between reliability and 
speed in clinical research can be dissolved, but only under adequate 
operational conditions for running large-scale, multi-arm adaptive trials. I 
use the notion of operational exceptionalism to depict the current situation 
in which adaptive trials can be successfully implemented only via 
“carefully orchestrated protocols” (London and Kimmelmann 2020, 477) 
in big research centers with close ties to industry and policy makers. In 
section 4, I present a cluster of adaptive measures developed as part of 
clinical research in precision medicine. New conditions under which 
adaptations can be preferred to fixed RCTs are identified. In section 5, the 
historical path to precision medicine is outlined. The focus is on the 
emergence of different biomedical initiatives in the big data era that have 
brought new ways of generating and assessing evidence, together with 
innovations in clinical research which are following up on the advances.  
 
The concluding section sums up the two arguments. Since the material, 
infrastructural, computational, and organizational conditions for 
conducting adaptive trials are at hand more than ever before, the case for 
their wider usage is made stronger. Still, there are practical and logistical 
drawbacks to the possibility of successfully implementing complex 
interventions such as adaptive trials across the board. Their recent 
successful uptake in assessing Covid-19 vaccines and treatments gives us 
much reason for optimism, but almost as much for caution. Adaptation 
should not mean that anything goes, but rather that everything is in place 
to make a balanced judgment based on available evidence and cooperative 
engagement of various interested parties. Inevitably, these hard choices are 
made in face of great uncertainty and nested interests.  
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2. Adaptive Trials in Epidemics 
 
In this section, I present two cases of adaptive trials conducted in the urgent 
context of an ongoing epidemic. In these cases adaptation was chosen as a 
consequence of exceptional circumstances, prompted by ethical reasons to 
balance potential harms in a particular way.  
 
The first case is the controversial AZT trial during the AIDS epidemic in 
the late 1980s, known for the groundbreaking role played by patient 
advocacy and citizen science (Epstein 1996). The first drug for AIDS, 
azidothymidine (AZT), was approved more quickly than subsequent 
therapies, in part because of the pressure for quick approvals coming from 
patients’ advocacy groups and the fact that there was no efficient therapy 
available. Although planned as a fixed, double-blinded, randomized, 
placebo-controlled trial, control groups were eventually excised from the 
trial so that more patients could get the medication immediately. This 
practice is considered adaptive by clinical research standards, as volunteers 
would normally be randomly assigned to either the treatment or the control 
arm equally, and the randomization ratio would be fixed until the end of 
the trial. Because there was no therapy for AIDS and the patients’ prospects 
were poor, many of them felt that they had nothing to lose. Potential harms 
associated with accelerated access to the experimental therapy were 
considered acceptable for many patients seeking help. In a record time, 
AZT was approved in 1987 after it had shown beneficial effects. However, 
the drug was not as successful as it was first thought. A three year follow 
up study of its effectiveness conducted on two thousand patients showed 
that patients in the placebo group were more likely to survive the three 
years of study than patients on AZT and that the drug had serious side 
effects and almost no benefits after a certain period of usage (Crewe 2018). 
It was later shown that AZT has beneficial effects, but only in combination 
with other medications, which is how it is still being prescribed and used. 
 
The AZT trial is controversial to date. Should the drug have been 
approved? At the time, patients were pressuring the FDA for quicker 
approval and the FDA responded by adjusting the standards to meet their 
requests. This was done without much understanding of either the virus, 
the intervention, or the alternative trial design. There was no concept of an 
‘adaptive trial’ at this stage––the trial was planned with a fixed design, 
only eventually accelerated, and adapted on the go. Concerns about patient 
recruitment and management strategies have been raised, such as the lack 
of coordination across twelve research centers that participated in the trial 
(Sonnabend 2011). There was a striking difference in mortality between 
the treatment and the control group (1 to 19 in the first 120 days) which 
decided in favor of expanding the treatment arm, but according to 
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Sonnabend, this discrepancy might have been an effect of biased patient 
selection and management. He also reports that the dose of initially 
administered AZT has been criticized for being too high. This might have 
led to beneficial short-term effects, but damaging long-term effects. 
Additionally, suspicions were raised about the practical limitations to 
blinding in such a study: The drug causes changes in routine blood counts 
that investigators need to see. Therefore we must conclude that 
investigators could know who was receiving AZT or placebo (Sonnabend 
2011).  
  
Doubts about the first AZT trial are primarily related to preference bias. 
Preference bias  
 
occurs when a research result unduly reflects the researchers’ 
preference for it over other possible results. (…) It works (…) 
by increasing the likelihood of the preferred outcome rather 
than by bluntly fabricating it. (Wilholt 2009, 92)  
 
It is not clear that this is what happened in the 1987 AZT trial, but if 
anything worrisome had happened, it seems to fall under the scope of 
preference bias. However, such subtle biasing is not attached to a particular 
design and it, unfortunately, permeates the landscape of biomedical and 
especially, pharmaceutical research (see Biddle 2007). Researchers, 
producers, policy makers, and patients had high hopes about AZT efficacy 
in absence of AIDS treatments. Everyone wanted the drug to work, and the 
trial was exceptional in both its urgent undertaking and its striking first 
outcomes.  
 
Despite possible problems with the trial, the regulators had good reasons 
to approve the drug in face of reported evidence. Besides, 
pharmacovigilance, or monitoring for side effects of the drugs on the 
market, is in place to identify problems that might have been missed on the 
scale of pre-approval research. Time-spans of drug activity, effects after 
prolonged usage, and usage for different subgroups of patients can differ 
drastically. Benefits, side-effects, and long-term effects show at different 
times, and risk is inevitable: between waiting for the approval too long 
(denying people access to potentially effective therapy) and granting the 
approval too quickly (allowing for the provision of ineffective or harmful 
therapy). The balance was struck in the AZT case on the side of quick yet 
possibly unreliable assessment, although promising at the time, as opposed 
to waiting for more evidence in face of great public outcry. The therapy 
was made available, followed up, and finally, restricted in use. In addition 
to ethical considerations about research in exceptional circumstances, the 
AZT trial brought to attention patients’ roles as advocates and partners in 
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healthcare decision-making. Today we find appeals to caution when it 
comes to such adaptations, but also tools and skills developed to plan and 
simulate a trial’s course should adaptive interventions be made (Pallmann 
et al. 2018, 10-11). Special care needs to be taken to ascertain the best 
dosage, optimal sample size and representativeness, and comparators to the 
experimental treatment. Additional staff and resources need to be in place 
to reconcile the need to make interim analysis with the need to keep the 
results blinded. Local discrepancies between research centers should be 
minimized by transparent protocols and centralized oversight. 
 
The second case has attracted philosophical attention both because of 
ethical challenges related to responses to emergencies and disasters (Calain 
2016), but also because of a conjoined ethical-epistemic interest in 
innovative trial design (Upshur and Fuller 2016; Varghese 2021a, 2021b). 
In 2015 a phase III trial called ‘Ebola ça Suffit!’ (‘Ebola, that’s enough!’) 
was conducted for testing recombinant vesicular stomatitis virus-Zaire 
Ebola vaccine (rVSV–ZEBOV) against Ebola virus disease. The design of 
the trial was not standard, due to time constraints, a limited amount of 
vaccine supplies, ethical concerns regarding the adoption of research 
methodology, and logistics and field operational challenges (Varghese 
2021a, 2021b; Calain 2018). ‘Ebola ça Suffit!’ was a result of collective 
efforts to respond to the 2013-2016 West African Ebola epidemic that had 
caused the death of more than 11,000 people (Calain 2018). In August 
2014, the Ebola epidemic was declared a public health emergency of 
international concern, and the World Health Organization (WHO) set up a 
panel of experts to consider ethical permissibility of testing potentially 
effective interventions for the disease in an accelerated manner. Within a 
few months, novel or repurposed therapeutic agents were tested for 
efficacy at various locations experiencing an outbreak.  
 
The ‘Ebola ça Suffit!’ ring trial used cluster randomization instead of 
individually controlled randomization, and a delayed vaccination arm as 
the control group instead of a placebo control group, to mitigate the 
transmission of the disease in case of evidence of efficacy. Upon 
confirming a case of the Ebola virus, a ring (cluster) of all infected persons’ 
contacts was established, as well as the contacts of their contacts (Henao-
Restrepo et al. 2017). The clusters were assigned to either immediate 
vaccination or a delayed vaccination arm, allowing both groups to receive 
the vaccine, as opposed to treating the control group with a placebo. The 
randomization stopped after four months to allow the immediate provision 
of the vaccine to more adults, and to include younger age groups sooner 
(WHO 2015). The vaccine was approved for ‘compassionate use’ in 
outbreaks, meaning that it had been proven sufficiently safe and effective 
to be recommended, although it had not yet been formally approved by a 
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full regulatory process. According to later correspondence in The Lancet, 
the efficacy estimate of the vaccine remained at 100% despite concerns 
about bias in the research design (Longini et al. 2018; Metzger and Vivas-
Martínez 2018). The vaccine eventually contributed to the suppression of 
the 2013-2016 Ebola virus disease epidemic (Geisbert 2017; Calain 2018). 
 
Upshur and Fuller (2016) draw on the lessons from Ebola trials to call for 
a philosophy of clinical trials, asserting that the “inherent trade-off 
between ethical requirements and scientific rigor” is not resolved 
“necessarily through insisting on validity over ethics, but rather in reaching 
consensus on what is at stake” (2016, 11). They characterize the successful 
implementation of the ring vaccination strategy as “evidence that 
alternative trial designs can work”, although they are not based on classical 
randomization which conventionally grants validity and reliability to 
clinical research. In a similar vein, Varghese (2021a, 2021b) uses the 
distinction between epistemic and non-epistemic values to argue that non-
epistemic values were rightfully prioritized over epistemic values in the 
case of ‘Ebola ca Suffit!’ The urgency of the intervention was prioritized 
over scientific understanding that a standard procedure would advance. In 
a situation in which it was necessary to stop the virus from spreading, 
cluster randomization was considered good enough and prioritized over 
individual randomization. It is important to note that randomization was 
not altogether avoided. Like in the AZT case, it was only adapted. In the 
AZT trial, control arms were dropped only when beneficial results after 
initial randomization were observed, while in ‘Ebola ca Suffit!’ 
randomization was applied to clusters as opposed to individuals. 
Additionally, control groups were excised only with a delay, when 
beneficial effects of the vaccine were observed. Adaptation thus did not 
replace randomization and controlling, it rather complemented them and 
made the trial feasible and apt given the circumstances.  
 
 
3. Towards Operational Exceptionalism 
 
In a recent article, London and Kimmelman (2020) argue against what they 
call pandemic research exceptionalism, according to which situations of 
crisis justify lowering research standards. They identify three problematic 
assumptions which underpin research exceptionalism. The first is that any 
evidence, even if flawed, is preferable to more demanding studies whose 
benefits show later. In other words, that evidence generated by a faster 
method is preferred to evidence generated by a slower method. The second 
is that scientific rigor conflicts with care. The third problematic assumption 
is that researchers and sponsors are allowed to exercise discretion over the 
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organization and design of research in times of crisis. These assumptions, 
they contend, underlie alarming practices in pandemic research.  
 
The proliferation of small studies that are not part of an 
orchestrated trajectory of development is a recipe for 
generating false leads that threaten to divert already scarce 
resources toward ineffective practices, slow the uptake of 
effective interventions because of an inability to reliably detect 
smaller but clinically meaningful benefits, and engender 
treatment preferences that make patients and clinicians 
reluctant to participate in randomized trials. (London and 
Kimmelman 2020, 476)  
 
The small studies referred to in this passage are numerous clinical trials 
that have been flourishing after the outbreak of the coronavirus epidemic, 
often investigating similar hypotheses in absence of coordinated oversight, 
rushing to publish results based on spurious correlations, and lacking 
adequate power to detect clinical benefit. Importantly, they are not a part 
of an “orchestrated trajectory of development”, in other words, of a 
coordinated translational enterprise. When London and Kimmelman 
complain about “patients and clinicians being reluctant to participate in 
randomized trials”, it is the adaptive randomized trials they refer to, which, 
according to them, hold a key to upholding both the standards of research 
excellence and time sensitivity.  
 
Sponsors, research consortia, and health agencies should 
prioritize research approaches that test multiple interventions, 
foster modularity, and permit timely adaptation. (…) Adaptive 
designs allow flagging interventions to be dropped quickly and 
promising alternatives to be added with fewer delays than 
would be incurred from the design and approval of new studies. 
(London and Kimmelman 2020, 477) 
 
The argument is that adaptive trials should be undertaken under careful 
coordination in big research centers with the ability to conduct and analyze 
them, and not that any adaptation will satisfy. Quite the contrary––
adaptation is here understood as a powerful, but demanding and complex 
method that can only work when five conditions of informativeness and 
social value are met, and under strict guidance and oversight.  
 
The conditions identified by London and Kimmelman are importance, 
rigorous design, analytical integrity, complete, prompt, and consistent 
reporting, and feasibility. The condition of importance requires that trials 
address evidence gaps, aiming to detect effects that are “realistic but 
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clinically meaningful” (London and Kimmelman 2020, 476). An example 
of bad practice would be to concentrate resources on identical clinical 
hypotheses, creating competition for recruitment, and a neglect of other 
hypotheses, as was the case at the time of hydroxychloroquine hype when 
many trials were conducted in the US to test its efficacy for alleviating 
Covid-19 symptoms. Rigorous design is ascertained by randomization, 
blinding, controlling, and using meaningful endpoints. An example of bad 
practice would be “to forego a dummy comparator and use a nonvalidated 
surrogate endpoint” (London and Kimmelman 2020, 477). Analytical 
integrity means that designs should be “prespecified in protocols, 
prospectively registered, and analyzed in accordance with 
prespecification” (2020, 477). An example of bad practice would be 
preregistering a trial with a particular design while reporting the results 
that are generated by using a different design. Challenges connected to 
reporting primarily concern the preference for reporting only positive 
results, thereby withdrawing important information about negative results 
from clinicians and health systems. Another challenge is ascertaining 
quality control because expert reviewers are a scarce resource. The last 
condition, feasibility, is especially challenging in a crisis. London and 
Kimmelman argue that this nonetheless should not mean that it is 
justifiable to trade it off against the other four conditions. An increase in 
feasibility does not mean a decrease in addressing important evidence 
gaps, allowing less rigorous design, neglecting analytical integrity, or 
failing to transparently report. They give particular guidelines to clinicians:  
 
Individual clinicians should avoid off-label use of unvalidated 
interventions that might interfere with trial recruitment and 
resist the urge to carry out uncontrolled, open-label studies. 
They should instead seek out opportunities to join larger, 
carefully orchestrated protocols to increase the prospect that 
high-quality studies will be completed quickly and generate the 
information needed to advance individual and public health. 
Academic medical centers can facilitate such coordination by 
surveying the landscape of ongoing studies and establishing 
mechanisms for “prioritization review” to triage studies. 
(London and Kimmelman 2020, 477) 
 
Channeling resources to orchestrated endeavors is a result of decades-long 
efforts to transform biomedical research towards better coordination and 
private-public partnerships, against the backdrop of the big data era that 
brought along the need to store, manage, and adequately use vast amounts 
of information and material. This portrays a picture in which the key to 
upholding standards for implementing adaptive design trials is in the hands 
of big research organizations with enough infrastructure and resources to 
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embark on such a complex task. I call this operational exceptionalism, in 
which centralization and coordination are the prerequisites for 
simultaneously increasing both the speed of generating evidence and the 
quality of this evidence. The only way to counter pandemic research 
exceptionalism seems to be by endorsing operational exceptionalism, 
according to which adaptive trials are not useful when run autonomously 
in local settings, but only when they are a part of larger projects based in 
selected research institutions. 
 
 
4. Adaptive Trials and Precision Medicine 
 
In this section, I focus on adaptive design as a clinical trial innovation that 
followed up on novel research methods and increased understanding of the 
intervention that is being assessed. In this cluster of cases, adaptive design 
trials are related to the rise of precision medicine.  
 
Personalized or precision medicine2 is an approach that tailors therapy to 
individual needs. It is often represented as ‘P4’ medicine: predictive, 
preventive, personalized, and participatory. The observations of highly 
variable drug responses have led to the development of a new scientific 
discipline from genetics, biochemistry, and pharmacology, namely 
pharmacogenetics, while advances in molecular medicine have led to a 
pharmacogenomics which seeks to understand the molecular mechanisms 
of drug response (Vogenberg, Barash, and Pursel 2010). In this new 
approach, patients’ gene variations guide the selection and dosage of drugs. 
Several adaptive measures have been introduced to evaluate precision 
medicine treatments and to match the well-responding subgroups of 
patients with promising therapies, improve access, and evaluate efficacy 
earlier and more efficiently.  
 
An example of an adaptive trial for a precision medicine intervention is the 
BATTLE-2 study––The Biomarker-integrated Approaches of Targeted 
Therapy for Lung Cancer Elimination 2 (Garralda et al. 2019). Results 
generated in the ‘adaptive phase’ inform the randomization to different 
drugs or combinations based on mutation profiles.  
 
 
2 Terms ‘personalized’ and ‘precision’ medicine are often used interchangeably, although personalized 
medicine is the older term, while precision medicine is currently the preferred one, at least according 
to the US National Research Council (NRC). NRC adopts the following definition of both terms: “the 
tailoring of medical treatment to the individual characteristics of each patient (…) to classify to a 
specific treatment” (NRC 2011, 12). ‘Precision medicine’ is preferred to avoid the interpretation that 
‘personalized’ means that each patient will be treated differently. 
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Instead of using a fixed model––built on the training data only–
adaptive strategies use the information on patients enrolled 
earlier in the testing set to continuously update the model and 
refine accrual throughout the entire study. (Garralda et al. 
2019, 551)  
 
Accrual design is a type of adaptive design––after the initial ‘learning 
phase’, in the ‘adaptive phase’ the ratio of patients randomly assigned to 
the experimental arm as opposed to the control arm changes to increase the 
proportion of patients in the arm that is performing better, which also 
increases the statistical power to detect clinical benefit (Garralda et al. 
2019, 551). Adaptive enrichment is a term that refers to the modification 
of the patient eligibility criteria: if analysis shows that one subgroup has a 
more favorable response, the trial can be ‘enriched’ by modifying it to 
either exclusively or predominantly enroll patients from this subgroup 
(Thorlund et al. 2018). The seamless adaptive trial design allows for 
proceeding from phase II to phase III trial in a non-standard way. The 
results from the phase II trial are used to determine the initial patient 
allocation ratio, the planned total sample size (which can be rather smaller 
than the usual phase III samples that normally include from 300 to several 
thousand patients), and a potentially enriched set of patients, those that are 
thought to benefit the most from the intervention (Thorlund et al. 2018). 
 
A significant part of the literature on adaptive trials, including guidelines 
for their implementation and reporting, comes from precision medicine 
research groups. They are raising problems related to their usage, but also 
providing means of addressing and overcoming them (for example, 
Garralda et al. 2019; Pallmann et al. 2018). Each trial is adapted in a 
particular way, so informed consent and the effective communication of 
risks and benefits to the patients can be a problem (Garralda et al. 2019, 
552). Funders are suspicious about the validity of adaptive trials or lack 
experience in evaluating them, so may decide against approving them 
(Garralda et al. 2019; Pallmann et al. 2018). Regulators alike may be 
unfamiliar with adaptive design (Pallmann et al. 2018, 4). Operational 
challenges such as managing preplanned adaptations together with 
blinding may require additional staff and experience, as data may leak 
more easily and reach the sponsors, compromising the integrity of the trial 
(Pallmann et al. 2018, 5).  
 
Overall, the efficacy of adaptive trials can be uncertain due to many 
factors, which are often local, contingent, and practical. Advocates of the 
usage of adaptive trials argue that these problems can be countered by 
transparent planning, careful execution, and the rigorous interpretation of 
the results. Additional skills in planning, conducting, and analyzing 
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adaptive design trials would need to be at hand, including statistical, 
mathematical, and modeling expertise. Since many clinicians are not 
trained in their usage, while the regulators are uncertain about their 
potential to avoid problems that the standard randomization and bias-
reducing measures are in place for, their wider usage is both called for and 
cautioned against, sometimes by the very same authors (like Pallmann et 
al. 2018 from the clinical medicine side) and regulatory documents (FDA 
2019). On the cautious side, it is emphasized that randomization and 
blinding remain the most reliable indicators of objectivity in clinical 
research and should not be bypassed in favor of shorter trials. A 
particularly problematic practice is reliance on non-randomized and non-
blinded studies, and avoidance of control groups. On the affirmative side, 
novel designs such as multi-arm and seamless design trials are 
characterized as being a well-understood, ethical and efficient way of 
doing clinical research.  
 
 
5. Adaptive Trials and the Productivity Crisis 
 
From another vantage point, the pharmaceutical industry is voicing hopes 
about the usage of adaptive trials as a means to end the productivity crisis 
(Mahlich, Bartol, and Dheban 2021). In this section, I place the emergence 
of adaptive trials in a wider context of biomedical movements initiated to 
improve the productivity and cost-benefit of biomedical research.  
 
Existing resources for the implementation of adaptive trials are a product 
of diverse measures in place to reform the pace and path by which 
biomedical innovations reach the market and patients. There is a consensus 
that pharmaceutical productivity has been going through a crisis for at least 
three decades (Munos 2009; Pammolli, Magazzini, and Riccaboni 2011; 
Taylor 2016). Advances in basic science resulting from stem cell research 
and the Human Genome Project (completed in 2003) have not resulted in 
clinical applications as quickly as was initially expected (Solomon 2015, 
161-163). The so-called ‘pipeline problem’ refers to the slowdown, instead 
of the expected acceleration, in innovative medical therapies reaching 
patients (FDA 2004), and what has thus been sought is the ‘uncorking of 
the bottleneck’ of pharmaceutical innovation. Furthermore, it has been 
estimated that it takes 17 years on average for research results to find 
implementation in clinical practice, which has been considered too slow 
(Morris et al. 2011). These problems have motivated different initiatives 
to transform the way biomedical research is conducted. Consequently, in 
the 2000s the idea of ‘translational research’ became a “buzzword” 
(Fishburn 2013, 487), a “mantra” (Maienschein et al. 2008, 43), “in vogue” 
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(Fang and Casadevall 2010, 563), and even “an imperative” (Harrington 
and Hauskeller 2014). 
 
The translational approach is based on the prospect of directly matching 
ideas for new therapies with the needs of patients observed in the clinic. It 
can be described as a cluster of accelerated transitions in the development 
of a medical product at the intersection of basic and clinical research, and 
more broadly, the intersection of prevention, guidelines, and health policy. 
These transitions are mostly accelerated by external, non-scientific 
measures: better communication between researchers from different 
disciplines, better communication between different stakeholders such as 
patients, researchers, regulators, and producers of therapies, 
interdisciplinary training, collection of databanks, and building of new 
research centers that would facilitate the interaction between basic and 
clinical research. Most of the philosophical work on translational medicine 
shares the view that it is hard to “find substance amidst the rhetoric” and 
that the movement “appears to offer no more than a metaphor” (Fuller 
2016). 
 
Robinson (2019) pointedly argues that attempts to find epistemic novelty 
in the new medical movements fail because their objectives are better 
assessed by a social epistemology approach attentive to market forces and 
financialized models of science and innovation. 
 
TrM (translational medicine) cannot be analyzed merely in 
terms of its epistemic novelty. After all, it has relocated 
research practices from the R&D departments of 
biopharmaceutical partners to university laboratories. (…) It 
is––in its current functionality––a structural configuration for 
the externalization of the costs and risks of early-stage 
biopharmaceutical research and development onto universities. 
(Robinson 2019, 4404)  
 
Translational initiatives are thus comprised of “questions, methods, areas 
of concern, and projects” which are “a product of a specific set of financial, 
commercial and industry-driven shifts” (Robinson 2019, 4404). 
 
Justification in terms of patient empowerment and acceleration of 
discovery and research is shared in both translational and precision 
initiatives. Both movements value speed in discovery, research, and 
development, which is not only a success of science but of a larger 
cooperative work and exchange of many stakeholders, institutions, and 
disciplinary cultures. Finally, it was the biobanks collected as part of 
translational initiatives in the early 2000s that have made it possible to 
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personalize medicine in the 2010s.3 Contemporary translations are very 
likely to occur on the terrain of precision medicine and they occur there 
faster due to changes in drug discovery methods and clinical assessment 
routes.4 In drug discovery, methods such as high-throughput screening can 
identify molecular targets among a vast number of potential matches 
(Adam 2011), and in clinical assessment, the adaptive design facilitates 
matching subgroups of patients with promising therapies based on genetic 
profiling. 
 
Against this backdrop, the emergence and development of adaptive designs 
can be traced to translational and precision medicine centers. Increased 
awareness of the need for trained statisticians, mathematicians, and big-
data experts in clinical research teams, and opening up to 
interdisciplinarity in a variety of contexts where singular expertise is not 
sufficient, have contributed to the fact that adaptive trials are nowadays 
planned, conducted, analyzed, and regulated with more understanding and 
expertise. However, this fact alone does not grant justification for their 
usage in every instance of clinical research. Clear rationale, transparent 
protocols, and importantly, operational conditions, need to be in place. It 
seems that especially operational conditions cannot be satisfied on smaller 
scales of individual clinics and local research centers, but rather 
“orchestrated” by big consortia with sufficient resources and in close 
cooperation with policy makers and industrial partners. The complexities 
that this operational exceptionalism brings in a value-laden and interest-
driven environment of biomedical research are beyond the scope of this 
paper but call for attention and discussion by philosophers and social 





The success of Covid-19 adaptive trials is not a consequence of research 
exceptionalism or lucky guesses, but of prior experience in healthcare 
crisis-management and structured efforts to reform biomedical research 
and innovation. That said, it is important to qualify the context in which 
adaptive trials are conducted and implemented. It is a private-public 
partnership of many stakeholders, highly burdened with both social 
commitments and commercial interests. Importantly, the apparent 
flexibility of adaptive trials is not as flexible as it may seem at first sight. 
 
3 Initiatives such as the NIH Roadmap in the US (NIH 2014) and the reforms outlined in the Cooksey 
Report (2006) in the UK. 
4 In 2017 the number of FDA approvals hit a two-decade high with 46 novel medicines, followed by 
59 approvals in 2018 (Mullard 2019). More precision medicines and tests were approved in 2017 than 
any year before (Bilkey et al. 2019), many of them based on biomarkers reliant on genetic testing.  
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They require both planning and rigor to be successful, just as much as fixed 
trials. The usual standards of rigor remain unchallenged in the new context, 
coming down to blinding, randomization, and controls. A new and most 
valuable element of their success is their speed. However, it is a qualified 
speed that, rather than trading off against reliability, requires reliability to 
achieve epistemic benefit. Daniel Steel (2010, 26-28) would call it an 
extrinsically epistemic value, i.e. a value that is not truth conducive per se 
but in combination with an intrinsically epistemic value like accuracy. 
Adaptive designs ground their reliability in “orchestration” and integration 
of different evidence and expertise. In the case of clinical trials, the benefits 
are both ethical––earlier access to therapies, and epistemological––earlier 
results that inform policies and further research. Still, adaptive design trials 
require additional resources and coordination, which is the most pressing 
practical obstacle to their wider, local implementation. They have been 
increasingly developed as a part of the precision medicine approach, and 
have recently been used to assess Covid-19 therapies. It is important to 
keep in mind though, that this does not grant them the status of the new 
standard. It means at best that the standard welcomes necessary upgrades 
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